Table 3.

Characteristics of patients with COVID-19 and cytolytic liver injury.

		AST or ALT ≥ 2 x ULN (n = 76)	AST or ALT < 2 x ULN (n = 206)	p-value	OR; (IC 95%)
F/M		20/56 (26.3%)	114/92 (55.3%)	< 0.0001	0.28 [0.16; 0.51]
BMI (kg/${\mathit{m}}^2)$	>25	27 (37.0%)	61 (30.7%)	0.3	1.33 [0.76; 2.33]
	>30	30 (39.5%)	88 (42.7%)	0.65	0.88 [0.51; 1.51]
Diabetes		20 (26.3 %)	63 (30.6%)	0.53	0.83 [0.46; 1.49]
Hypertension		34 (45.3%)	94 (45.6%)	0.97	0.99 [0.58; 1.68]
Heart Failure		8 (10.7 %)	24 (11.7%)	0.82	0.91 [0.38; 2.11]
COPD		1 (1.3%)	1 (0.5%)	0.46	2.77 [0.17; 44.9]
>1 comorbidity		19 (28.2%)	58 (25.3%)	0.64	0.87 [0.47; 1.58]
Treatments	NSAIDs	0 (0.0%)	0 (0.0%)	–	–
	Immunosuppressant	5 (6.7%)	6 (2.9%)	0.15	2.8 [0.71; 8.05]
	Liver toxic drugs	41 (54.7%)	72 (35.0%)	0.003	2.24 [1.31; 3.84]
	Hydroxychloroquin	34 (45.9%)	38 (18.7%)	< 0.0001	3.68 [2.07; 6.58]
Admission in ICU		30 (40.0%)	13 (6.3%)	< 0.0001	9.90 [4.78; 20.48]
CT scan injury > 50%		53 (71.6%)	81 (39.7%)	< 0.0001	3.83 [2.15; 6.83]
Death		20 (26.7%)	25 (12.1%)	0.003	2.63 [1.36; 5.10]